orforglipron

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

After so many announcements of new facility builds in the US, Eli Lilly has made a welcome commitment to a European investment.

News

Eli Lilly has built the case for its oral GLP-1 orforglipron with two more phase 3 readouts, including a head-to-head win over Farxiga in diabetes.

News

Lilly has named Houston as the second of four locations for new manufacturing facilities that are central to a $27bn investment programme in the US.

News

Novo Nordisk has trumpeted data showing oral Wegovy matched the injectable version in a phase 3 trial, ramping up pressure on rival Eli Lilly.

News

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.